RT Journal Article
SR Electronic
T1 Flipping the odds of drug development success through human genomics
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 170142
DO 10.1101/170142
A1 Aroon D. Hingorani
A1 Valerie Kuan
A1 Chris Finan
A1 Felix A. Kruger
A1 Anna Gaulton
A1 Sandesh Chopade
A1 Reecha Sofat
A1 Raymond J. MacAllister
A1 John P. Overington
A1 Harry Hemingway
A1 Spiros Denaxas
A1 David Prieto
A1 Juan Pablo Casas
YR 2017
UL http://biorxiv.org/content/early/2017/07/30/170142.abstract
AB Drug development depends on accurately identifying molecular targets that both play a causal role in a disease and are amenable to pharmacological action by small molecule drugs or bio-therapeutics, such as monoclonal antibodies.Errors in drug target specification contribute to the extremely high rates of drug development failure.Integrating knowledge of genes that encode druggable targets with those that influence susceptibility to common disease has the potential to radically improve the probability of drug development success.